You are here

Commercialization of a Diagnostic test for amyotrophic lateral sclerosis (ALS)

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 4R42NS083227-02
Agency Tracking Number: R42NS083227
Amount: $950,698.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: 101
Solicitation Number: PA12-089
Timeline
Solicitation Year: 2013
Award Year: 2014
Award Start Date (Proposal Award Date): 2014-06-01
Award End Date (Contract End Date): 2016-08-31
Small Business Information
21053 N 75TH ST
Scottsdale, AZ 85255-4771
United States
DUNS: 078507192
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 ROBERT BOWSER
 (412) 383-7819
 bowserrp@upmc.edu
Business Contact
 LORRIN BOWSER
Phone: (480) 636-1357
Email: lorrinbowser@ironhorsedx.com
Research Institution
 ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER
 
350 WEST THOMAS ROAD
PHOENIX, AZ 85013-4409
United States

 Domestic nonprofit research organization
Abstract

DESCRIPTION provided by applicant Amyotrophic lateral sclerosis ALS or Lou Gehrigandapos s disease is a fatal neurodegenerative disease with a typical lifespan of years after diagnosis The initial symptoms can be similar to many other neurologic disorders and often begin with limb weakness muscle fasciculations or increasing difficulties in speech or breathing No definitive diagnostic tests currently exist for ALS and clinical diagnosis typically
takes months from symptom onset and relies on ruling out other potential causes of the clinical symptoms Earlier diagnosis will permit more rapid initiation of treatment with newer drug
therapies in development or equally important provide a means to rapidly rule out ALS as a cause of the symptoms Iron Horse Diagnostics Inc was created to finalize the development of diagnostic and prognostic indicators of ALS and market these assays as laboratory developed tests LDTs in a Clinical Laboratory Improvement Amendments CLIA certified lab We have produced a series of peer reviewed publications convincingly demonstrating that significant levels of pNfH and complement c can be detected in the blood and CSF of ALS patients and that the levels detected by our assays provide diagnostic utility for ALS We propose a series of tasks to optimize and validate our assays in a CLIA certified laboratory the last remaining steps before commercialization This is a FastTrack application because the remaining steps before Phase III are well defined with highly definable go no go gates During Phase I of the proposed work we will finalize and optimize assays as diagnostic indicators of ALS by testing samples for indicative proteins and translating the assay technology onto a new platform Phase II will expand on this by conducting a multi center prospective clinical research study and qualifying the assays using patient samples in a CLIA certified lab to determine the overall accuracy of the ALS diagnostic The goal of this proposal is to generate a sensitive and validated LDT Lab Developed Test for these biomarkers useful for clinically diagnosing ALS in a CLIA certified lab A certified LDT will be marketed to clinicians as a service PUBLIC HEALTH RELEVANCE Amyotrophic lateral sclerosis ALS is a fatal neurodegenerative disease that currently lacks a diagnostic test Iron Horse Diagnostics has cerebrospinal fluid and blood based diagnostic assays that in our application will be qualified validated and commercialized as a laboratory developed test LDT for ALS

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government